Literature DB >> 16501577

CD30 is a survival factor and a biomarker for transformed human pluripotent stem cells.

Daniella Herszfeld1, Ernst Wolvetang, Emma Langton-Bunker, Tung-Liang Chung, Adam A Filipczyk, Souheir Houssami, Pegah Jamshidi, Karen Koh, Andrew L Laslett, Anna Michalska, Linh Nguyen, Benjamin E Reubinoff, Irene Tellis, Jonathan M Auerbach, Carol J Ording, Leendert H J Looijenga, Martin F Pera.   

Abstract

The application of human embryonic stem (hES) cells in regenerative medicine will require rigorous quality control measures to ensure the safety of hES cell-derived grafts. During propagation in vitro, hES cells can acquire cytogenetic abnormalities as well as submicroscopic genetic lesions, such as small amplifications or deletions. Many of the genetic abnormalities that arise in hES cell cultures are also implicated in human cancer development. The causes of genetic instability of hES cells in culture are poorly understood, and commonly used cytogenetic methods for detection of abnormal cells are capable only of low-throughput analysis on small numbers of cells. The identification of biomarkers of genetic instability in hES cells would greatly facilitate the development of culture methods that preserve genomic integrity. Here we show that CD30, a member of the tumor necrosis factor receptor superfamily, is expressed on transformed but not normal hES cells, and that CD30 expression protects hES cells against apoptosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16501577     DOI: 10.1038/nbt1197

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  44 in total

1.  Derivation, propagation and controlled differentiation of human embryonic stem cells in suspension.

Authors:  Debora Steiner; Hanita Khaner; Malkiel Cohen; Sharona Even-Ram; Yaniv Gil; Pavel Itsykson; Tikva Turetsky; Maria Idelson; Einat Aizenman; Rita Ram; Yael Berman-Zaken; Benjamin Reubinoff
Journal:  Nat Biotechnol       Date:  2010-03-28       Impact factor: 54.908

2.  Differences between karyotypically normal and abnormal human embryonic stem cells.

Authors:  S Yang; G Lin; Y-Q Tan; L-Y Deng; D Yuan; G-X Lu
Journal:  Cell Prolif       Date:  2010-06       Impact factor: 6.831

Review 3.  hESC adaptation, selection and stability.

Authors:  C Grandela; E Wolvetang
Journal:  Stem Cell Rev       Date:  2007       Impact factor: 5.739

Review 4.  Deconstructing human embryonic stem cell cultures: niche regulation of self-renewal and pluripotency.

Authors:  Morag H Stewart; Sean C Bendall; Mickie Bhatia
Journal:  J Mol Med (Berl)       Date:  2008-06-03       Impact factor: 4.599

5.  Stem Cell Surface Marker Expression Defines Late Stages of Reprogramming to Pluripotency in Human Fibroblasts.

Authors:  Jordan E Pomeroy; Shelley R Hough; Kathryn C Davidson; Alex M Quaas; Jordan A Rees; Martin F Pera
Journal:  Stem Cells Transl Med       Date:  2016-05-09       Impact factor: 6.940

Review 6.  Potential barriers to therapeutics utilizing pluripotent cell derivatives: intrinsic immunogenicity of in vitro maintained and matured populations.

Authors:  Chad Tang; Micha Drukker
Journal:  Semin Immunopathol       Date:  2011-04-11       Impact factor: 9.623

Review 7.  The tumorigenicity of human embryonic and induced pluripotent stem cells.

Authors:  Uri Ben-David; Nissim Benvenisty
Journal:  Nat Rev Cancer       Date:  2011-03-10       Impact factor: 60.716

8.  Integrated chemical genomics reveals modifiers of survival in human embryonic stem cells.

Authors:  Robert Damoiseaux; Sean P Sherman; Jackelyn A Alva; Cory Peterson; April D Pyle
Journal:  Stem Cells       Date:  2009-03       Impact factor: 6.277

Review 9.  The stem cell identity of testicular cancer.

Authors:  Amander T Clark
Journal:  Stem Cell Rev       Date:  2007-01       Impact factor: 5.739

10.  Astrocytes derived from trisomic human embryonic stem cells express markers of astrocytic cancer cells and premalignant stem-like progenitors.

Authors:  Sailesh Gopalakrishna-Pillai; Linda E Iverson
Journal:  BMC Med Genomics       Date:  2010-04-27       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.